2018 Protein Expression Therapies Treatment 
Drug Discovery World
JUNE 14, 2023
The recent clinical trial for metastatic breast cancer patients (DESTINY-Breast04) found that a treatment traditionally used for HER2 positive patients was also effective in patients considered HER2 negative. It used the current CAP/ASCO testing algorithm for HER2 protein expression levels.
Drug Target Review
SEPTEMBER 4, 2023
10 Reported cAMP as the second messenger signalling molecule conserved from bacteria to humans and modulates several biological processes, including protein expression, gene transcription, and cell development and differentiation. International research and symposium help to understand and combat regional challenges. Suruchi, A.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
APRIL 30, 2024
Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.
The Pharma Data
SEPTEMBER 28, 2021
The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to 6 weeks aged and data supporting the continued clinical investigation of gene therapy, SRP-9001, in Duchenne dystrophy (DMD).
Drug Discovery World
JANUARY 23, 2023
Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment.
The Pharma Data
JANUARY 13, 2021
Dr. Lederman continued, “Despite the recognized promise of anti-CD40-ligand mAb therapy, first generation anti-CD40-ligand mAbs were limited because their crystallizable fragment (Fc) domain interacted with a cell surface receptor called Fc?RII, antagonist receptor fusion protein. 1 Lederman, S. 1 Lederman, S. International Immunol. (11):1583
Drug Discovery World
SEPTEMBER 5, 2022
The success of targeted therapies in cancer comes on the heels of identifying specific molecular targets resulting from genetic variations. Modulations in protein expression levels or the presence of dysfunctional proteins observed in individuals with specific mutations act as biomarkers in selecting patients for targeted therapies. .
Expert insights. Personalized for you.
130 
Let's personalize your content